Phase 2 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with acute myeloid leukemia (a type of blood cancer, but not the specific subtype called acute promyelocytic leukemia) or high-risk myelodysplastic syndrome (a condition where the bone marrow doesn't make enough healthy blood cells), based on 2016 WHO diagnostic standards
- People aged 60 or older
- People whose general physical health and ability to carry out daily activities falls within a certain range on a standard medical fitness scale (confirm with trial site for exact details)
- People whose kidneys are functioning well enough, measured by a specific calculation of how well the kidneys filter the blood (a result of 30 mL/min or above)
- People whose liver enzyme levels and bilirubin (a substance processed by the liver) are within an acceptable range — no more than 3 times the upper limit of normal for liver enzymes, and no more than 2 times the upper limit of normal for bilirubin
- People whose heart is pumping efficiently enough, as shown by a heart ultrasound result of 50% or above
- People with a life expectancy of more than 8 weeks
- People who are willing and able to give informed consent and follow the study requirements
Who may not be able to join:
- People under the age of 60
- People who have already received chemotherapy treatment for their condition
- People with significant active heart problems, such as irregular heartbeat that is not controlled, high blood pressure that is not controlled, heart failure, severe heart disease (grade 3 or 4 on a standard heart health scale), or a heart attack within the 6 months before screening
- People with other serious illnesses that could interfere with taking part in the trial, such as severe active infections or diabetes that is not under control
- People who are unable to understand the study plan or provide informed consent
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Weiyan Zheng, MD, Zhejiang University
Phone: 86-13857187088
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Complete response rate(CR+CRi)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.